Sublingual fentanyl orally disintegrating tablet in daily practice: Efficacy, safety and tolerability in patients with breakthrough cancer pain

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1385-1394

  Überall, Michael A ^a   Müller Schwefe, Gerhard H H ^b  

^a Institute for Quality Assurance in Pain Therapy and Palliative Care   (Germany)

^b Interdisciplinary Pain and Palliative Care Center (Interdisziplinares Schmerz und Palliativzentrum)   (Germany)

Author keywords

Breakthrough pain; Cancer; Efficacy; Fentanyl; Safety; Sublingual administration; Transmucosal

Indexed keywords

FENTANYL;

ADULT; AGED; ANOREXIA; ARTICLE; BLURRED VISION; CANCER PAIN; CLINICAL PRACTICE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; RASH; SOMNOLENCE; TABLET DISINTEGRATION; VOMITING;

ADMINISTRATION, SUBLINGUAL; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PROFESSIONAL PRACTICE; TABLETS; TREATMENT OUTCOME;

EID: 79958844393     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.583231     Document Type: Article

References (22)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81. (Pubitemid 20187930)
2. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83. (Pubitemid 38771657)
3. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34. (Pubitemid 29199908)
4. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part I - assessment. P&T 2005;30:296-301. (Pubitemid 40734311)
5. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part II - management. P&T 2005;30:354-61. (Pubitemid 40885216)
6. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharmaceut Sci 1998;1:15-30.
7. Instanyl® SPC. Nycomed UK Ltd. Date of revision: July 2009.
8. Actiq® SPC. Flynn Pharma Ltd, Republic of Ireland. Date of revision: October 2010.
9. Abstral® Sublingual Tablets SPC. ProStrakan Group Ltd, UK. Date of revision: February 2010.
10. Effentora® SPC. Cephalon Ltd, UK. Date of revision: January 2010.
11. Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 2011; 27:519-30.
12. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85.
13. Dillmann U, Nilges P, Saile H, et al. Assessing disability in chronic pain patients. Schmerz 1994;8:100-10.
14. Herrmann C, Scholz KH, Kreuzer H. Psychologic screening of patients of a cardiologic acute care clinic with the German version of the Hospital Anxiety and Depression Scale. Psychother Psychosom Med Psychol 1991;41:83-92.
15. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003; 25:406-11. (Pubitemid 36506668)
16. Tait RC, Pollard CA, Margolis RB, et al. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil 1987;68:438-41. (Pubitemid 17105053)
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70. (Pubitemid 13098606)
18. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19. (Pubitemid 40038441)
19. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009;3:1-6.
20. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135-41.
21. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30. (Pubitemid 32274181)
22. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11 (Pubitemid 44627444)